Ingrid Blanc-Brisset
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ingrid Blanc-Brisset has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Luc de Haro
Clinical Pharmacology, Poison Control Center, Ste Marguerite Hospital, Marseille, France
1 shared publication - Lucia Tichadou
Centre Antipoison, Hôpital Salvator, 249 Boulevard Sainte Marguerite, 13009 Marseille, France
1 shared publication - Maryvonne Hayek-Lanthois
Centre Antipoison, Hôpital Salvator, 249 Boulevard Sainte Marguerite, 13009 Marseille, France
1 shared publication - Mathieu Glaizal
APHM, Hôpital Sainte Marguerite, Clinical Pharmacology and Poison Control Centre, 13274 Marseille, France
1 shared publication
Latest Publications
- Open Access
Asp Viper (Vipera aspis) Envenomation: Experience of the Marseille Poison Centre from 1996 to 2008
A retrospective case review study of viper envenomations collected by the Marseille’s Poison Centre between 1996 and 2008 was performed. Results: 174 cases were studied (52 grade 1 = G1, 90 G2 and 32 G3). G1 patients received symptomatic treatments (average hospital stay 0.96 day). One hundred and six (106) of the G2/G3 patients were treated with the antivenom Viperfav* (2.1+/-0.9 days in hospital), while 15 of them received symptomatic treatments only (plus one immediate death) (8.1+/-4 days in hospital, 2 of them died). The hospital stay was significantly reduced in the antivenom treated group (p < 0.001), and none of the 106 antivenom treated patients had immediate (anaphylaxis) or delayed (serum sickness) allergic reactions. Conclusion: Viperfav* antivenom was safe and effective for treating asp viper venom-induced toxicity.
Open AccessAsp Viper (Vipera aspis) Envenomation: Experience of the Marseille Poison Centre from 1996 to 2008
A retrospective case review study of viper envenomations collected by the Marseille’s Poison Centre between 1996 and 2008 was performed. Results: 174 cases were studied (52 grade 1 = G1, 90 G2 and 32 G3). G1 patients received symptomatic treatments (average hospital stay 0.96 day). One hundred and six (106) of the G2/G3 patients were treated with the antivenom Viperfav* (2.1+/-0.9 days in hospital), while 15 of them received symptomatic treatments only (plus one immediate death) (8.1+/-4 days in hospital, 2 of them died). The hospital stay was significantly reduced in the antivenom treated group (p < 0.001), and none of the 106 antivenom treated patients had immediate (anaphylaxis) or delayed (serum sickness) allergic reactions. Conclusion: Viperfav* antivenom was safe and effective for treating asp viper venom-induced toxicity.